12
2017
-
06
A real-world research program seminar on the effectiveness of Huaiqihuang granules in the treatment of primary nephrotic syndrome in children was held in Hangzhou.
On the morning of June 10, 2017, the seminar on "real world research on the effectiveness of huaiqihuang granules in the treatment of primary nephrotic syndrome in children" sponsored by qidong gaitianli pharmaceutical co., ltd. was held in Shangri-La hotel in Hangzhou city. this is the second large sample clinical study of huaiqihuang granules after the real world study of 3000 cases of bronchial asthma in children. The Children's Hospital affiliated to the Capital Institute of Pediatrics is the team leader, and CRO Company Beijing Zero Krypton is responsible for monitoring the implementation. A total of 17 authoritative medical institutions in the field of children's kidney participated in the meeting.
The meeting was presided over by Professor Chen Chaoying, the main researcher, and introduced the overall goal and significance of Huaiqihuang Granules in the treatment of primary nephrotic syndrome in children. Glucocorticoids have always been recognized as the first choice for the treatment of nephrotic syndrome. Children with initial hormone therapy can be completely relieved, but they are prone to relapse, and some children have hormone resistance. This is a very difficult problem encountered in clinical work. Therefore, it is very important to explore the efficacy and safety of Huaiqihuang Granules in the treatment of primary nephropathy in children.
Lu Zhengxin, deputy general manager of Qidong Gaitianli Pharmaceutical Co., Ltd., introduced the basic research of Huaiqihuang Granules in nephropathy, hoping to apply the latest research of Huaiqihuang Granules to clinical trials of primary nephrotic syndrome in children and expect to achieve gratifying results.
At the meeting, Professor Chen Chaoying introduced the first draft of the research plan for the treatment of primary nephrotic syndrome with Huaiqihuang Granules, and discussed the plan and answered questions with the experts attending the meeting, and finally formed a preliminary opinion. After further improvement, we look forward to the successful holding of the plan as soon as possible. Launch meeting. Li Liping, general manager of Beijing Zero Krypton Company, gave a detailed introduction to registered research, IV clinical research and real world research.
We wish the issue of children's kidney an early adoption of ethics and a formal program kick-off meeting.
More news
Address
1166 West Nanyuan Road, Qidong Economic Development Zone, Jiangsu Province
Telephone
Mobile website
Public Number
Copyright © 2024 Qidong Gaitianli Pharmaceutical Co., Ltd.